drugset / Trial / NCT03687372

Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03687372

Phase 3 Completed 503 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Timeline

Start
2018-09-17
Primary completion
2019-06-20
Completion
2019-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 45 % Topical

Indications